Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

"GSK’s speciality medicines soar while generals drop, Q2 results reveal " was originally created and published by ...

GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...

GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

Glaxo (GSK) delivered earnings and revenue surprises of +9.82% and +3.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are ...